MICROBIOME DRIVEN LIQUID BIOPSY™
The diagnostic implications of microbiome markers in tissue and liquid biopsies are endless, and Micronoma is the first company developing a platform to use these markers in blood to detect early-stage cancer
REDEFINING EARLY STAGE DETECTION WITH ONCOBIOTA™
Our Oncobiota™ platform technology is designed to detect cancer in early stages (I and II), utilizing pioneering microbial research, next gen sequencing and AI, with great sensitivity and specificity.
ONE CANCER AT A TIME, STARTING WITH LUNG
We are dedicated to bringing advanced diagnostic services to physicians one cancer at a time. By adding targeted tools to the physician toolkit, we are dedicated to achieving actionable results that can lead to cost savings and more lives saved. Learn more here.
“There are more microbes in the human body than there are stars in the galaxy. With this much information to tackle, we are converging advances in the understanding of cancer, microbiome, molecular technologies, and big data science into new, exciting capabilities to diagnose disease early and save lives. We have a line of sight on powerful new solutions that we believe could revolutionize the standard of care.”
Sandrine Miller-Montgomery, CEO & Co-Founder of Micronoma
THE PROBLEM
MILLION
New cancer cases
worldwide each year
MILLION
Cancer deaths each year
Sung, H. et. al.(2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, 71(3), 209–249.
Solution:
OncobiotaTM
The diagnostic implications of microbiome markers in tissue and liquid biopsies are endless. As the only cancer diagnostic company that is developing a diagnostic platform technology using the microbiome to detect early-stage cancer, Micronoma has the cutting-edge advantage.
Our patent pending Oncobiota™ platform is designed to reveal cancer-related microbiome with high specificity and sensitivity. We are actively developing a minimally invasive and precise microbiome-driven liquid biopsy™ laboratory-developed test (LDT) for detecting cancer in its earliest stages, unlike tests that only focus on the human genome, epigenome, or cancer mutations.
Oncobiota™ has the potential to be applied to many cancer types. Starting with lung cancer, which has the highest need for early detection in terms of incidence and mortality rates, we believe our innovative LDT technology can make a big difference in the lives of the many patients affected by cancer each year.
“Our novel proprietary method for detecting specific microbiome biomarkers in a simple blood draw is designed to offer a revolutionary new option for early cancer detection.”
Rob Knight, PhD, Co-Founder of Micronoma
Humans and Microbes
Humans and microbes co-exist in a mutually beneficial relationship in our bodies. Microbes can be found naturally not only in our stools, but also in our mouths, tissues, and blood, even when we are healthy.
The Microbiome
The microbiome is the community of all the microbes—bacteria, fungi, protozoa, and viruses—that live on and inside the human body. The composition of the microbiome changes with many factors such as location in the body, lifestyle, and gender. If analyzed properly, the microbiome can reveal the status of our health.
Microbes and Cancer
Microbes are now known to be found in human tissues, including cancer tissues and blood. Micronoma’s proprietary platform and global expertise allow for the development of innovative LDTs for identification of microbial signatures in circulating blood that are predictive of a cancerous tumor. This type of minimally invasive liquid biopsy LDT uses blood samples, which can be more easily collected than solid tissue samples.
Latest News
Forbes 30 Under 30 North America 2023 Healthcare
Forbes has named Micronoma CAO and Co-founder Gregory Sepich-Poore one of its 30 Under 30 in Healthcare for 2023. Read more at Forbes.
Meet us at these upcoming conferences
PRECEDE, Pancreatic Cancer Early Detection Consortium Annual Meeting and Biomarker Summit. New York, NY. December 7-8, 2022.
Precision Medicine World Conference (PMWC 2023). Silicon Valley, CA. January 25-27, 2023.
Awards & Recognition
2021 Unicorn Battle Silicon Valley
Website Terms of Use, Privacy Policy, and Licenses
Micronoma, INC., CLIA #05D2253538
Oncobiota™ LDT is under development and is currently not available for commercial use in any jurisdiction. Once available under CLIA license, Oncobiota™ will be available in the United States by prescription only.
Contact Us
If you have questions or would like to learn more, please email us at info@micronoma.com or learn about joining our team at Careers.
Micronoma
6342 Ferris Square
San Diego, CA 92121